Related Experiment Video
Updated: May 11, 2026

Real-Time Monitoring and Modulation of Blood Pressure in a Rabbit Model of Ischemic Stroke
Published on: February 10, 2023
The lower, the better? : fractional polynomials meta-regression of blood pressure reduction on stroke risk
Hisato Takagi1, Takuya Umemoto
1Department of Cardiovascular Surgery, Shizuoka Medical Center, 762-1 Nagasawa, Shimizu-cho, Sunto-gun, Shizuoka, 411-8611, Japan, kfgth973@ybb.ne.jp.
Insights
Lowering systolic blood pressure (SBP) significantly reduces stroke risk. However, excessive SBP reduction beyond 13.7 mmHg with single-drug therapy offers no additional stroke risk reduction in primary prevention.
Area of Science:
- Cardiovascular Medicine
- Clinical Pharmacology
- Epidemiology
Background:
- Blood pressure (BP) lowering drugs significantly reduce stroke risk.
- A 10 mmHg reduction in systolic BP (SBP) or 5 mmHg in diastolic BP is associated with a one-third reduction in stroke incidence.
Purpose of the Study:
- To determine the optimal extent of BP lowering for stroke risk reduction.
- To investigate potential limits to BP reduction benefits in primary prevention.
Main Methods:
- Meta-regression analysis of 17 primary-prevention trials.
- Utilized fractional polynomials for flexible, non-linear modeling of SBP reduction and stroke risk.
- Calculated relative risks (RRs) for stroke incidence based on SBP reduction.
Main Results:
- An inverse J-shaped dose-response relationship was observed between SBP reduction and stroke risk.
- The nadir, or optimal point for stroke risk reduction, occurred at a 13.7 mmHg SBP reduction.
- The best-fitting model showed a significant gain in deviance compared to a linear model.
Conclusions:
- Single-drug therapy for BP lowering may have a threshold for stroke risk reduction.
- Reductions in SBP exceeding 13.7 mmHg in primary prevention settings do not appear to offer further stroke risk benefits.
- These findings suggest a potential limit to the benefits of intensive BP lowering with monotherapy.
Objective:
Lowering systolic blood pressure (BP) (SBP) by 10 mmHg or diastolic BP by 5 mmHg using any of the main classes of BP lowering drugs reduces stroke by about a third. The objective of the present study is to determine whether there is a limit to the extent to which BP should be lowered.
Methods:
From the individual 17 primary-prevention trials of single drug therapy included in a recent meta-analysis, we abstracted reductions in SBP (SBP reduction in the treatment group minus that in the control group [mmHg]) and data regarding incidence of stroke to generate relative risks (RRs). We performed "flexible" (not "linear") unrestricted maximum likelihood meta-regression, using fractional polynomials, of the reduction in SBP on the risk of stroke.
Results:
The best-fitting model offered a gain in deviance of 5.71 with respect to the reference linear model, according to the expected inverse J-shaped (nadir at a 13.7-mmHg reduction in SBP) dose-response relation between reductions in SBP and logarithmic RRs for stroke.
Conclusions:
More than 13.7-mmHg SBP reduction with single drug therapy could produce no longer additional reduction in the risk of stroke in a primary-prevention setting.
Related Concept Videos
Atherosclerosis III: Management
Regression Toward the Mean
Pre-Procedural Guidelines for Assessing Blood Pressure
Factors affecting Blood pressure
Physiological Factors:
Hypertension and Regulation of Blood Pressure
Measurement of Blood Pressure